212 related articles for article (PubMed ID: 9162756)
1. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
Morand OH; Aebi JD; Dehmlow H; Ji YH; Gains N; Lengsfeld H; Himber J
J Lipid Res; 1997 Feb; 38(2):373-90. PubMed ID: 9162756
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4'-(6-allyl-ethyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin.
Peffley DM; Gayen AK; Morand OH
Biochem Pharmacol; 1998 Aug; 56(4):439-49. PubMed ID: 9763219
[TBL] [Abstract][Full Text] [Related]
3. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.
Mark M; Muller P; Maier R; Eisele B
J Lipid Res; 1996 Jan; 37(1):148-58. PubMed ID: 8820110
[TBL] [Abstract][Full Text] [Related]
4. Effects of a 2,3-oxidosqualene-lanosterol cyclase inhibitor 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line HepG2.
Dollis D; Schuber F
Biochem Pharmacol; 1994 Jul; 48(1):49-57. PubMed ID: 8043030
[TBL] [Abstract][Full Text] [Related]
5. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.
Telford DE; Lipson SM; Barrett PH; Sutherland BG; Edwards JY; Aebi JD; Dehmlow H; Morand OH; Huff MW
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2608-14. PubMed ID: 16210564
[TBL] [Abstract][Full Text] [Related]
6. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo.
Eisele B; Budzinski R; Müller P; Maier R; Mark M
J Lipid Res; 1997 Mar; 38(3):564-75. PubMed ID: 9101437
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
8. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
Burton PM; Swinney DC; Heller R; Dunlap B; Chiou M; Malonzo E; Haller J; Walker KA; Salari A; Murakami S
Biochem Pharmacol; 1995 Aug; 50(4):529-44. PubMed ID: 7646560
[TBL] [Abstract][Full Text] [Related]
9. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase.
Thoma R; Schulz-Gasch T; D'Arcy B; Benz J; Aebi J; Dehmlow H; Hennig M; Stihle M; Ruf A
Nature; 2004 Nov; 432(7013):118-22. PubMed ID: 15525992
[TBL] [Abstract][Full Text] [Related]
10. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
11. Induction of CYP3A by 2,3-oxidosqualene:lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes.
Shenoy SD; Spencer TA; Mercer-Haines NA; Abdolalipour M; Wurster WL; Runge-Morris M; Kocarek TA
Mol Pharmacol; 2004 May; 65(5):1302-12. PubMed ID: 15102959
[TBL] [Abstract][Full Text] [Related]
12. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.
Chuang JC; Valasek MA; Lopez AM; Posey KS; Repa JJ; Turley SD
Biochem Pharmacol; 2014 Apr; 88(3):351-63. PubMed ID: 24486573
[TBL] [Abstract][Full Text] [Related]
13. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
[TBL] [Abstract][Full Text] [Related]
14. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.
Rowe AH; Argmann CA; Edwards JY; Sawyez CG; Morand OH; Hegele RA; Huff MW
Circ Res; 2003 Oct; 93(8):717-25. PubMed ID: 14512442
[TBL] [Abstract][Full Text] [Related]
15. Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear.
Huff MW; Telford DE
Trends Pharmacol Sci; 2005 Jul; 26(7):335-40. PubMed ID: 15951028
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.
Liang Y; Besch-Williford C; Aebi JD; Mafuvadze B; Cook MT; Zou X; Hyder SM
Breast Cancer Res Treat; 2014 Jul; 146(1):51-62. PubMed ID: 24878988
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
18. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
20. Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells.
Sawada M; Matsuo M; Hagihara H; Tenda N; Nagayoshi A; Okumura H; Washizuka K; Seki J; Goto T
Eur J Pharmacol; 2001 Nov; 431(1):11-6. PubMed ID: 11716837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
